Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Summary

To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Eligibility

Inclusion Criteria:

* Aged ≥18 and older
* Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
* HR+/HER2-
* ECOG 0-3
* Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors

Exclusion Criteria:

* During pregnancy or lactation
* Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption

Conditions2

Interventions1

Related trials

• An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy — Fudan University
• Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer — Fudan University
• CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer — RenJi Hospital
• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer — Wenjin Yin

Browse More Trials